| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 228.71 | 9.2% | 59.6% |
| Total Income | 231.31 | 9.6% | 60.1% |
| Expenditure | 206.58 | 8.2% | 57.4% |
| PBT | 24.73 | 19.8% | 73.7% |
| Net Profit | 18.42 | 19.1% | 72.3% |
| OPM | 13.39% | 0.70pp | 3.23pp |
| NPM | 7.96% | 0.94pp | 3.53pp |
| EPS | 1.60 | 19.2% | 72.3% |
Margin collapse and capex bets: IPL's guidance was already cut — Q2 confirms it
Net profit crashed 72.3% YoY and margins compressed below management's revised targets. The quarter wasn't a miss — it was proof that prior guidance was overstated and has now been reset downward twice in two quarters.
₹18.4 Cr
-72.3% YoY
8.0%
vs 27% prior
13.4%
below 14.4% claim & 15–18% prior target
₹100 Cr
received; execution begins Q3
India Pesticides' Q2 earnings print is a study in sequential downward revisions. Revenue collapsed 59.6% to ₹228.7 Cr, and net profit fell 72.3% to ₹18.4 Cr—not because the quarter was a surprise, but because management had already reset expectations lower in Q1, and Q2 confirmed that earlier reset was insufficient. The core tension: the company is caught between domestic structural weakness (monsoon deficiency, weak herbicide demand) and a capex bet (Hamirpur expansion, ₹120–135 Cr total) whose returns remain speculative. Export orders provide a lifeline—₹100 Cr just received—but have not yet translated to revenue.
The cascade of guidance cuts
Claims vs. what held up on the call
"Confident of maintaining EBITDA margin at 14.4%"
Reality: Q2 OPM delivered 13.4%, below stated 14.4% and prior 15–18% target
"Hamirpur facility progressing on schedule"
Reality: Only 2 of 10 blocks operational; 2 more expected early FY28, not H2 FY27
"Export orders provide support for outlook" (~₹100 Cr received)
Reality: Orders confirmed; execution begins Q3 onwards. Partial execution Q2 (~₹88–89 Cr run-rate implied in H1 ₹177 Cr export revenue). Unproven at scale
"Formulation sales showing momentum"
Reality: ₹111 Cr in Q2 vs ₹72 Cr in Q1 — genuine Q-o-Q growth, but from weak base
Where the profit disappeared
The ₹72.3% collapse in net profit traces to three causes. First, domestic demand withered: monsoon deficiency and erratic rainfall disrupted paddy, kharif, and horticulture planting across Maharashtra, Andhra Pradesh, Karnataka, Punjab, and Haryana. Herbicide application weakened sharply; Q2 revenue fell 59.6% YoY. Second, margins compressed: EBITDA margin fell 380 bps to 14.4% (from 18.2% prior year) due to higher employee costs, freight inflation, forex losses, and job-work charges (₹12 Cr in Q2, up from ₹6 Cr in Q2 FY26). Backward integration (75% complete) has not yet offset cost inflation. Third, capex drag is front-loaded: ₹65 Cr capitalized to Hamirpur in September; infrastructure is in place but capacity ramp is behind prior guidance.
Implied ₹50–70 Cr Q2
weak herbicide application, monsoon
-380 bps YoY
18.2% → 14.4%; wages, freight, forex
₹12 Cr Q2
vs ₹6 Cr Q2 FY26; masks underlying margin pressure
The bull-bear ledger
Export orders (₹100 Cr) now materializing; Europe & Australia market entry
Regulatory approvals (UK, Argentina) provide new market optionality; 8 products in pipeline
Formulation scaling (₹111 Cr Q2) — higher margin business; capex not yet absorbed
Intermediate backward integration (75% complete) — Pretilachlor now in-house
Operating cash flow healthy: ₹48 Cr H1; net cash position ₹36 Cr vs ₹29 Cr March
Domestic demand collapse (-59.6% revenue YoY) with no near-term recovery visible
Margin compression unresolved; OPM 13.4% below stated targets; backward integration benefits delayed
Hamirpur capex (₹120–135 Cr total) front-loaded; returns speculative; subsidiary unproven
Guidance credibility weak: revenue halved, margin targets cut 160–360 bps in 2 quarters
Export orders unproven at scale; geopolitical risk and supply-chain volatility cited as portfolio drivers
Ranked risks: what should concern a holder
Domestic demand remains structurally weak
HighMonsoon deficiency persists into H2 FY27. Revenue guidance already defensive (maintenance, not growth). Herbicide demand may not snap back; cumulative -59.6% YoY is not a cyclical blip.
Margin recovery contingent on multiple moving parts
HighEBITDA margin 14.4% vs. 15–18% target. Backward integration benefits delayed. Freight/forex headwinds persist. Formulation scaling and capex absorption critical to margin recovery; no guarantee.
Hamirpur capex execution and subsidiary losses
High₹120–135 Cr capex total, ₹65 Cr already capitalized. Only 2 of 10 blocks operational. Subsidiary expected ₹40–50 Cr H2 revenue (unproven); possible losses until scale achieved. Capital-heavy bet with uncertain ROI.
Export order book concentration and fulfillment risk
Medium₹100 Cr orders from unnamed Europe/Australia customers. Execution depends on supply-chain stability and geopolitical conditions. If major customer defaults or supply disrupts, order book at risk.
Regulatory approval ramp-up uncertain
MediumArgentina ₹20–25 Cr Y1 target is conservative. UK expansion needs to prove at customer pull. 8 products in pipeline (Australia, Brazil, Canada, Asia) carry approval and market-entry risk.
Guidance credibility collapse
MediumManagement has cut revenue guidance, margin targets, and Hamirpur ramp twice in two quarters. Next miss triggers rating downgrade and further FII outflow.
How the market is reading it
The stock's price action tells the story. IPL trades at ₹117.15, down 72.87% from its all-time high of ₹431.75, and sits below all major moving averages (SMA20 ₹119.13, SMA50 ₹128.19, SMA200 ₹147.61). The stock is 7.22% above its 52-week low of ₹109.26—technical weakness, not recovery. More damning: FII ownership has collapsed to 0.20% in Q1 FY27 from 1.87% in Q4 FY26—a 1.67 percentage-point exodus in a single quarter. Promoter ownership remains stable at 63.65%, but the institutional vote of confidence has fled.
Bulk dealing activity in mid-September (around ₹144) showed mixed flows—brokers cycling positions—but no sustained institutional demand. The combination of margin compression, guidance downgrades, and FII exit suggests the market views IPL as a story in distress, not recovery. The 73% drawdown from ATH is not noise; it reflects real structural problems.
The honest debate
What to watch next (Q3 and beyond)
1 · Export order execution begins (Q3 onwards)
₹100 Cr in hand. Q3 should show material export revenue uptick if execution is real. Track: export revenue trajectory in Q3 vs. ₹88–89 Cr run-rate seen in H1 and partial execution in Q2.
2 · Hamirpur blocks 3–4 operational, subsidiary revenue ramp
Management guided ₹40–50 Cr H2 subsidiary revenue. Q3 results will confirm if 2 new blocks are online and revenue is materializing. This is the capex returns test.
3 · Domestic demand stabilization
Post-monsoon planting patterns will show in Q3–Q4. If herbicide application accelerates and domestic revenue grows Q-o-Q, the structural weakness narrative breaks. If it remains flat/negative, the downside case hardens.
4 · Margin trajectory
The single number to track: OPM. If it stays below 14%, backward-integration story is unconvincing. If it moves toward 15–16%, the margin-recovery narrative is alive. Watch also: job-work charges in Q3 (should trend lower as Hamirpur capacity absorbs conversion in-house).
India Pesticides is not having a bad quarter. It is having the quarter of a company in structural transition, and the transition is not working as promised. Revenue collapsed, margins compressed below targets, and management has reset guidance lower twice in two quarters. Export orders and new approvals are genuine, but immaterial at current scale. Capex is front-loaded and returns are lagging. The FII exodus (0.20% ownership, down from 1.87%) is a vote of no-confidence.
The stock's 73% drawdown from ATH is not an opportunity to buy the dip. It is the market correctly pricing in the execution risk and credibility loss. Until domestic demand stabilizes, capex delivers revenue at promised margins, and management restores credibility through execution, the burden of proof is on the company, not the bear case.
Verdict: Hold. The number to track: OPM in Q3–Q4. If it stays below 14%, the margin-recovery story is dead and further downside likely. If it moves to 15–16%, the story resets.
Margin miss, guidance cut — export orders insufficient offset for weak FY27 start
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Margin guidance revised downward Q1→Q2; delivered OPM 13.4% below stated 14.4%; Hamirpur revenue halved (₹50–60 Cr from ₹70–100 Cr prior)
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 revenue plunged 59.6% YoY and net profit fell 72.3% due to weak domestic demand and deficient rainfall; margins compressed below guidance despite management claims. Export orders (~₹100 Cr) and new regulatory approvals (UK, Argentina) provide near-term support and long-term optionality, but execution risk is high: Hamirpur is behind schedule (2 of 10 blocks live), capex ramp is steep (₹120–135 Cr total), and management has already cut FY27 guidance from prior calls (margin target down 15–18% from 18–20%, revenue growth from lower single-digit to defensive "maintenance").
₹228.7 Cr
Revenue · −59.6% YoY₹18.4 Cr
Reported PAT · −72.3% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Confident of maintaining EBITDA margin at 14.4%
OVERSTATEDQ2 OPM 13.4%, below stated 14.4% EBITDA margin and prior 15-18% target
Export orders provide support for outlook
MET₹100 Cr orders received; export revenue H1 ₹177 Cr (only ~88-89 Cr in Q2 on run-rate)
Hamirpur facility progressing on schedule
OVERSTATEDOnly 2 of 10 planned blocks operational; 2 more expected early next year (slower than ₹50-60 Cr FY27 prior guidance)
Revenue should be similar to last year
MISSQ2 revenue -59.6% YoY; H1 revenue -15.9% YoY — clear miss vs last-year levels
Formulation sales showing momentum
METFormulation revenue ₹111 Cr in Q2 vs ₹72 Cr in Q1 — valid growth Q-o-Q but off low base
Earnings quality
What changed since the last call
Revenue guidance cut
DowngradeQ1 FY27 call: 'lower single-digit growth' for FY27. Q2 call: 'maintain last year's revenue' (defensive; implies flat-to-negative growth vs FY26's ₹579 Cr).
EBITDA margin target cut
DowngradeQ1 FY27: target 15–18% (vs prior 18–20%). Q2 FY27: management now saying 'maintain 14.4% achieved this quarter' — below the 15–18% range just stated.
Hamirpur capex expected backloaded
DowngradePrior guidance ₹50–60 Cr revenue FY27. Now only 2 of 10 blocks operational, 2 more expected next year. Clear slowdown vs prior ₹70–100 Cr guidance.
Export orders materializing
UpgradeQ1 FY27: no specific order visibility. Q2 FY27: ₹100 Cr export orders received (Europe, Australia); execution to begin Q3.
Regulatory approvals accelerating
UpgradeUK technical equivalence + Argentina registration completed this quarter; 4+ more products applied for in Europe; 8 products in pipeline for Australia/Brazil/Canada/Asia.
The Q&A
Soft Q&A overall. Analysts asked specific questions (raw sourcing, capex, Hamirpur progress, export scale) and management answered with numbers, but did not face hard pushback on the magnitude of YoY margin compression or the miss vs guidance. Tone was constructive; analysts seemed satisfied with the defensive narrative and forward catalysts.
Raw material sourcing, EBITDA margin outlook — Vidhi Shah, C.R. Kothari & Sons Stock
Partial65% sourced from India, 20% from China, rest other countries. Confident of maintaining EBITDA margin achieved this quarter despite supply-chain volatility and freight cost increases.
Customer demand, Hamirpur facility progress — Vidhi Shah, C.R. Kothari & Sons Stock
AnsweredShalvi progressing as planned; 2 blocks in operation, 10 blocks will operate slowly next year, 2 more blocks planned and operational most probably next year. Portfolio being revisited due to geopolitical situation and supply-chain issues.
Product backward integration percentage — Vidhi Shah, C.R. Kothari & Sons Stock
AnsweredAlmost 75% of products are backward integrated. Intermediates being imported now are being produced in-house; example: Pretilachlor intermediate has been brought in-house, imports now stopped.
Revenue guidance for FY27 — Yogansh, Mittal Analytics
PartialOverall situation is very tough to estimate, but we should be able to maintain the revenue we achieved last year.
Export order composition and growth expectations — Yogansh, Mittal Analytics
AnsweredWe received orders for this and next quarter; mix of technical and bulk formulation. We got some orders last quarter (dull). Now we have some speed. These are existing molecules being formulated. Will cover shortfall in H1; at least want to cover H1 gap in coming 6 months.
Argentina and UK market opportunity — Yogansh, Mittal Analytics
AnsweredAnticipating at least first year INR 20–25 crores from Argentina single molecule; working on second molecule. UK: already have existing customers; agreement finalized in Argentina. Both products for India sale also as well as exports; Argentina is fresh market.
Capex guidance and subsidiary progress — Saket Kapoor, Kapoor & Company
PartialWe are trying to bridge the gap lagged in the first quarter. At least we want to cover this up in coming 6 months. Situation slightly difficult; need to adjust to existing revenue numbers slightly.
Property/plant capitalization and capex detail — Saket Kapoor, Kapoor & Company
AnsweredMain capitalization in subsidiary during September (~₹65 Cr). Under stabilization; expecting turnover of ₹40–50 Cr during H2 current year. Subsidiary capex ₹80–90 Cr; main entity ₹40–45 Cr. Infrastructure cost ₹40 Cr incremental capex; asset turnaround 2x next year.
Capex guidance annual total — Saket Kapoor, Kapoor & Company
AnsweredCapex guidance for IPL is ₹40–45 Cr on track. For subsidiary ₹80–90 Cr. Revisiting the second phase need arises; will find it.
Export order scale and geography — Giriraj Daga, Visaria Family Trust
AnsweredOrders from Europe and Australia; about INR 100 crores size now. Have executed partly; will execute in coming months.
Shalvi portfolio changes rationale — Giriraj Daga, Visaria Family Trust
PartialDue to geopolitical situation, raw material availability difficult, prices fluctuated, demand pattern changing. Revisiting complete portfolio, especially for subsidiary. Expansion in place; product portfolio may get slightly modified.
Product portfolio and Shalvi multipurpose usage — Giriraj Daga, Visaria Family Trust
AnsweredApproval is similar to existing approved products; selecting from existing basket. Existing, revisiting portfolio. Instead of product A, product B has better chance. Plant slightly multipurpose; both products can fit with minor changes.
Capex guidance for FY27 — Giriraj Daga, Visaria Family Trust
AnsweredIPL capex guidance ₹40–45 Cr on track. Subsidiary ₹80–90 Cr projected. Revisiting second phase as per need.
Next-year capex step-up — Giriraj Daga, Visaria Family Trust
AnsweredNext year, it will be step-up again; no problem at all.
Guidance
FY27 full-year revenue maintain last year
LowQ2 FY26 base was ₹579 Cr (H1) and ₹295 Cr (Q2 alone). Current run-rate suggests FY27 will be 15–20% lower; defensive language indicates capex-constrained capex confidence.
EBITDA margin maintain 14.4% achieved Q2
MediumBelow prior Q1 target of 15–18% and prior-prior 18–20%. Management cites confidence in input cost management and backward integration, but no upside.
Gross margin remain ~50% (per Gupta commentary)
MediumSupported by product mix shift to formulations (higher margin) but offset by job-work charges (₹12 Cr Q2) and freight/forex headwinds.
IPL parent capex ₹40–45 Cr FY27; subsidiary ₹80–90 Cr
HighTotal ₹120–135 Cr vs prior ₹100 Cr guidance. Hamirpur phase 1 complete (₹65 Cr capitalized Sept); phase 2 to follow. Subsidiary ₹40–50 Cr H2 revenue targeted.
Next year (FY28) capex step-up again
MediumManagement indicated continued investment; no specific number given. Suggests infrastructure expansion will continue but magnitude unclear.
Risks the call surfaced
Domestic demand weakness
HighMonsoon deficiency and erratic rainfall disrupted paddy, kharif, and horticultural cropping; herbicide application weak. Domestic demand remains subdued; no recovery visible in Q2 or expected near-term.
Margin compression unresolved
HighEBITDA margin fell 380 bps YoY (18.2% → 14.4%) due to higher employee costs, freight, forex losses, and job-work charges (₹12 Cr Q2). Backward integration story (75% complete) has not yet offset inflation. Management's 'maintain 14.4%' language indicates no near-term improvement.
Hamirpur capex execution risk
HighHamirpur facility 2 of 10 blocks operational; 2 more expected 'early next year' (i.e., Feb–Mar 2027, not H2 FY27). Prior guidance ₹50–60 Cr FY27 revenue now looks unachievable. Capex ₹65 Cr already capitalized in Sept; full ₹120–135 Cr/year commitment is high leverage on speculative returns.
Regulatory approval execution and geopolitical risk
MediumNew regulatory approvals (UK, Argentina) completed but market entry is early-stage; Argentina target ₹20–25 Cr year 1 (conservative); UK expansion dependent on customer pull. Geopolitical disruption cited as driver for portfolio revision; supply-chain resilience uncertain. 8 products in registration pipeline carry approval risk across Australia, Brazil, Canada, Asia.
Export order book concentration and fulfillment risk
MediumExport orders (~₹100 Cr) described as Europe & Australia; no customer name disclosed. Fulfillment depends on supply-chain stability (freight, raw material cost volatility) and geopolitical conditions. If major customer defaults or supply chain disrupts, ₹100 Cr book is at risk.
Management
Score 6/10. Clear and factual on operational metrics (revenue, margin, capex, blocks operational). Transparent on challenges (monsoon, freight, forex). But: hedged significantly on forward guidance (shifted from growth to maintenance), deflected on geopolitical reasons for portfolio revision, and downplayed magnitude of margin compression. Mixed track record. Hamirpur capex progressing but slower than prior guidance (₹50–60 Cr FY27 → 2 of 10 blocks only). Backward integration 75% complete (credible). Formulation sales momentum genuine (₹111 Cr Q2). But: missed EBITDA margin targets (13.4% OPM vs 14.4% claimed, vs 15–18% Q1 target).
1 · Q3 FY27 (Jan 2027)
Export order execution begins; inventory normalization expected
2 · H2 FY27 (Jan–Mar 2027)
Hamirpur Block 3 + 4 expected operational; ₹40–50 Cr subsidiary revenue ramp
3 · Nov 2026 onwards
UK/Argentina product distribution agreements begin; initial ₹20–25 Cr from Argentina single molecule
Export orders (~₹100 Cr) and new regulatory approvals (UK, Argentina) provide near-term support and long-term optionality, but execution risk is high: Hamirpur is behind schedule (2 of 10 blocks live), capex ramp is steep (₹120–135 Cr total), and management has already cut FY27 guidance from prior calls (margin target down 15–18% from 18–20%, revenue growth from lower single-digit to defensive "maintenance").